Literature DB >> 3198502

Pradimicin, a novel class of potent antifungal antibiotics.

T Oki1, M Konishi, K Tomatsu, K Tomita, K Saitoh, M Tsunakawa, M Nishio, T Miyaki, H Kawaguchi.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3198502     DOI： 10.7164/antibiotics.41.1701

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  32 in total

1.  Synergistic actions of tailoring enzymes in pradimicin biosynthesis.

Authors:  Kandy Napan; Shuwei Zhang; Whitney Morgan; Thomas Anderson; Jon Y Takemoto; Jixun Zhan
Journal:  Chembiochem       Date:  2014-08-22       Impact factor: 3.164

2.  A toxic substance produced by Nocardia otitidiscaviarum isolated from cutaneous nocardiosis.

Authors:  Y Mikami; S F Yu; K Yazawa; K Fukushima; A Maeda; J Uno; K Terao; N Saito; A Kubo; K Suzuki
Journal:  Mycopathologia       Date:  1990-11       Impact factor: 2.574

3.  Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.

Authors:  A H Groll; T Sein; V Petraitis; R Petraitiene; D Callender; C E Gonzalez; N Giri; J Bacher; S Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  C E Gonzalez; A H Groll; N Giri; D Shetty; I Al-Mohsen; T Sein; E Feuerstein; J Bacher; S Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative.

Authors:  M Kakushima; S Masuyoshi; M Hirano; M Shinoda; A Ohta; H Kamei; T Oki
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 8.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H.

Authors:  Christophe Marchand; John A Beutler; Antony Wamiru; Scott Budihas; Ute Möllmann; Lothar Heinisch; John W Mellors; Stuart F Le Grice; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.